Becton, Dickinson and Company (NYSE:BDX) Stock Price Expected to Rise, Piper Sandler Analyst Says

Becton, Dickinson and Company (NYSE:BDX) had its price target boosted by stock analysts at Piper Sandler from $175.00 to $200.00 in a research note issued to investors on Friday, Benzinga reports. The brokerage currently has a “neutral” rating on the medical instruments supplier’s stock. Piper Sandler‘s price objective suggests a potential downside of 6.12% from the company’s previous close.

A number of other research firms also recently weighed in on BDX. Barclays began coverage on shares of Becton, Dickinson and Company in a research note on Wednesday, October 7th. They set an “underweight” rating and a $165.00 price target on the stock. Zacks Research upgraded Becton, Dickinson and Company from a “hold” rating to a “strong-buy” rating in a report on Wednesday, October 21st. Jefferies Financial Group reaffirmed a “buy” rating and set a $242.00 price target on shares of Becton, Dickinson and Company in a report on Thursday. Wells Fargo & Company increased their price objective on Becton, Dickinson and Company from $161.00 to $170.00 and gave the stock an “equal weight” rating in a research report on Friday, August 7th. Finally, Stifel Nicolaus set a $195.00 price target on Becton, Dickinson and Company in a research report on Friday, August 7th. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, eight have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Becton, Dickinson and Company presently has a consensus rating of “Moderate Buy” and an average target price of $188.87.

Becton, Dickinson and Company Stock Up 1.8%

BDX opened at $213.05 on Friday. The company has a market capitalization of $58.70 billion, a PE ratio of 64.17, a P/E/G ratio of 14.10 and a beta of 0.22. Becton, Dickinson and Company has a one year low of $127.59 and a one year high of $214.78. The stock’s fifty day moving average is $187.69 and its 200-day moving average is $170.23. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.51 and a current ratio of 0.87.

Becton, Dickinson and Company (NYSE:BDX) last announced its earnings results on Thursday, November 5th. The medical instruments supplier reported $4.15 EPS for the quarter, topping the consensus estimate of $4.07 by $0.08. Becton, Dickinson and Company had a net margin of 4.52% and a return on equity of 14.79%. The company had revenue of $5.27 billion during the quarter, compared to analysts’ expectations of $5.11 billion. During the same period last year, the company posted $3.96 earnings per share. The business’s revenue for the quarter was up 5.4% on a year-over-year basis. On average, equities analysts predict that Becton, Dickinson and Company will post 12.67 EPS for the current fiscal year.

Becton, Dickinson and Company declared that its board has initiated a share repurchase plan on Thursday, November 5th that authorizes the company to repurchase 10,000,000 outstanding shares. This buyback authorization authorizes the medical instruments supplier to repurchase up to 3.6% of its stock through open market purchases. Stock buyback plans are generally a sign that the company’s management believes its stock is undervalued.

Insider Buying and Selling at Becton, Dickinson and Company

In other news, EVP Michael Feld sold 165 shares of Becton, Dickinson and Company stock in a transaction dated Wednesday, August 26th. The shares were sold at an average price of $188.49, for a total value of $31,100.85. Following the completion of the transaction, the executive vice president owned 19,720 shares in the company, valued at $3,717,022.80. This trade represents a 0.83% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Roland Goette sold 2,438 shares of the firm’s stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $180.84, for a total value of $440,887.92. Following the completion of the transaction, the executive vice president owned 14,856 shares of the company’s stock, valued at approximately $2,686,559.04. This represents a 14.10% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 6,907 shares of company stock worth $1,269,128. Corporate insiders own 0.40% of the company’s stock.

Hedge Funds Weigh In On Becton, Dickinson and Company

A number of hedge funds and other institutional investors have recently bought and sold shares of BDX. Maryland Capital Advisors Inc. boosted its stake in Becton, Dickinson and Company by 13,900.0% in the third quarter. Maryland Capital Advisors Inc. now owns 140 shares of the medical instruments supplier’s stock worth $25,000 after buying an additional 139 shares in the last quarter. Trifecta Capital Advisors LLC lifted its stake in Becton, Dickinson and Company by 59.0% in the third quarter. Trifecta Capital Advisors LLC now owns 167 shares of the medical instruments supplier’s stock worth $30,000 after acquiring an additional 62 shares during the period. Meeder Asset Management Inc. raised its stake in Becton, Dickinson and Company by 152.2% in the first quarter. Meeder Asset Management Inc. now owns 169 shares of the medical instruments supplier’s stock worth $27,000 after buying an additional 102 shares in the last quarter. Main Street Group LTD purchased a new position in shares of Becton, Dickinson and Company in the 1st quarter valued at approximately $29,000. Finally, Bell Investment Advisors Inc purchased a new stake in Becton, Dickinson and Company in the second quarter worth about $29,000. Hedge funds and other institutional investors own 86.97% of the company’s stock.

Key Becton, Dickinson and Company News

Here are the key news stories impacting Becton, Dickinson and Company this week:

• Positive Sentiment: Q4 adjusted EPS of $4.15 and revenue of $5.3 billion topped estimates; revenue grew 5.4% year over year. For FY2026, free cash flow rose 42.5% to $2.9 billion, a sign of improved cash generation. BD Reports Fourth Quarter and Full Year Fiscal 2026 Financial Results
• Positive Sentiment: BD authorized repurchases of up to 10 million shares—about 3.6% of shares—and raised its quarterly dividend 1% to $1.06, extending its annual dividend-increase streak to 55 years. BD Board Increases Dividend and Authorizes Share Repurchases
• Positive Sentiment: Evercore ISI raised its price target to $230 from $210, indicating a more favorable analyst view. Evercore ISI Adjusts Becton, Dickinson and Company Price Target
• Negative Sentiment: The main concern is the fiscal 2027 outlook: revenue growth guidance was viewed as subdued and slightly below expectations, tempering the impact of the quarterly beat and prompting a negative reaction in premarket trading. BD Q3 CY2026 Beats on Revenue, but Full-Year Guidance Comes in Below Expectations

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company, commonly known as BD, is a global medical technology company that develops, manufactures and sells a broad range of products used by healthcare providers, clinical laboratories, pharmaceutical companies and patients. Its offerings support medication delivery, diagnostics, infection prevention, surgical care and other clinical procedures.

BD’s products include needles, syringes, injection devices, intravenous administration systems, medication-management technologies, specimen-collection products, diagnostic systems and laboratory instruments.